Alpha Cognition Inc

For Q2 2026, ZUNVEYL generated approximately $6 million in net product revenue, up about 71% sequentially from approximately $3.5 million in Q1. Total revenue was $6.1 million versus $1.7 million in the prior-year period. GAAP gross product margin was approximately 94%, based on about $6 million of net product sales and roughly $400 thousand of product cost. Net loss was $8.8 million, or $0.40 per share, compared with a net loss of $13.2 million, or $0.82 per share, in the prior-year period. Operating expenses were $13.5 million, including $11.5 million of SG&A and $2 million of R&D. Cash and cash equivalents were $41.4 million as of June 30, 2026. For full-year 2026, operating expense guidance was cut to $50 million to $54 million from $54 million to $58 million. Management did not give revenue guidance, but said it remains on track for operating profitability in 2027 and that 2027 expense guidance will be provided later.

Michael E. McFadden framed Q2 as another commercialization milestone for ZUNVEYL, emphasizing sequential demand growth, broader prescriber adoption, more nursing home penetration, and positive evidence-generation progress. He said the company is deploying capital intentionally into the highest-return areas: expanding prescriber reach, building real-world evidence, and unlocking payer access. His tone was confident but still measured, repeatedly noting the product is early in its commercial phase and that the team is focused on disciplined execution toward operating profitability in 2027.

Henry Du highlighted the hard numbers: $6 million in net product revenue, $6.1 million in total revenue, 94% gross product margin, $13.5 million in operating expenses, and $8.8 million in net loss, or $0.40 per share. He said cash and cash equivalents were $41.4 million at quarter-end, with $57.9 million in total current assets, $6.4 million in current liabilities, and about $51.5 million in working capital. He also pointed to the early settlement of the Galantos Pharma royalty obligation as a capital-structure simplification that removes future royalty burden and improves long-term product economics. Finally, he lowered 2026 operating expense guidance to $50 million to $54 million, citing operating discipline and confidence in balancing growth investment with efficiency.

Analysts focused on repeat prescribing behavior, when the company might expand beyond long-term care into neurology or retail, and when payer access could become a real tailwind. Management said repeat prescribing mostly reflects experience with the drug over 2 to 3 months and cited tolerability, cognition, and behavioral benefit as the main reasons prescribers keep writing ZUNVEYL. On expansion, management said it wants to maximize the long-term care opportunity first and would only consider neurology after operating profitability and stronger payer coverage. On access, they said formulary conversations are ongoing and still expect potential improvement in the second half of 2026. Other questions covered demand in Q3, stocking, gross-to-net, adherence, discontinuation, and market size; management said there was no significant stocking, gross-to-net is holding around 74%, adherence is still being tracked, and patient discontinuations are more often due to frailty, hospitalization, or administrative/reimbursement issues than drug tolerability or lack of efficacy.